These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 7493370

  • 1. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
    Richman CM, DeNardo SJ, O'Grady LF, DeNardo GL.
    Cancer Res; 1995 Dec 01; 55(23 Suppl):5916s-5920s. PubMed ID: 7493370
    [Abstract] [Full Text] [Related]

  • 2. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, Wu AM, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2000 Oct 01; 6(10):3855-63. PubMed ID: 11051230
    [Abstract] [Full Text] [Related]

  • 3. Importance of timing of radioimmunotherapy after granulocyte colony-stimulating factor administration for peripheral blood stem cell harvest.
    Juweid ME, Blumenthal RD, Lew W, Hajjar G, Rubin AD, Goldenberg DM.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3337s-3342s. PubMed ID: 10541383
    [Abstract] [Full Text] [Related]

  • 4. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME, Hajjar G, Stein R, Sharkey RM, Herskovic T, Swayne LC, Suleiman S, Pereira M, Rubin AD, Goldenberg DM.
    J Nucl Med; 2000 Jan 01; 41(1):93-103. PubMed ID: 10647610
    [Abstract] [Full Text] [Related]

  • 5. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW, Long GD, Stockerl-Goldstein KE, Johnston LJ, Chao NJ, Negrin RS, Blume KG.
    Clin Cancer Res; 1999 Nov 01; 5(11):3411-8. PubMed ID: 10589752
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy.
    Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM.
    Clin Cancer Res; 2000 Sep 01; 6(9):3621-8. PubMed ID: 10999754
    [Abstract] [Full Text] [Related]

  • 7. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.
    Richman CM, DeNardo SJ, O'Donnell RT, Goldstein DS, Shen S, Kukis DL, Kroger LA, Yuan A, Boniface GR, Griffith IJ, DeNardo GL.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3243s-3248s. PubMed ID: 10541370
    [Abstract] [Full Text] [Related]

  • 8. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab')2.
    Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, Goldenberg DM.
    J Nucl Med; 1996 Sep 01; 37(9):1504-10. PubMed ID: 8790202
    [Abstract] [Full Text] [Related]

  • 9. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
    Prince HM, Gardyn J, Millward MJ, Rischin D, Francis P, Gates P, Chapple P, Quinn M, Juneja S, Wolf M, Januszewicz EH, Richardson G, Scarlett J, Briggs P, Brettell M, Toner GC.
    Bone Marrow Transplant; 1999 Mar 01; 23(5):427-35. PubMed ID: 10100555
    [Abstract] [Full Text] [Related]

  • 10. A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
    Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5842-52. PubMed ID: 14676105
    [Abstract] [Full Text] [Related]

  • 11. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
    Behr TM, Wörmann B, Gramatzki M, Riggert J, Gratz S, Béhé M, Griesinger F, Sharkey RM, Kolb HJ, Hiddemann W, Goldenberg DM, Becker W.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
    [Abstract] [Full Text] [Related]

  • 12. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies.
    Juweid M, Swayne LC, Sharkey RM, Dunn R, Rubin AD, Herskovic T, Goldenberg DM.
    Gynecol Oncol; 1997 Dec 01; 67(3):259-71. PubMed ID: 9441773
    [Abstract] [Full Text] [Related]

  • 13. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
    Juweid ME, Zhang CH, Blumenthal RD, Hajjar G, Sharkey RM, Goldenberg DM.
    J Nucl Med; 1999 Oct 01; 40(10):1609-16. PubMed ID: 10520699
    [Abstract] [Full Text] [Related]

  • 14. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma.
    Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L.
    J Nucl Med; 1995 Apr 01; 36(4):586-92. PubMed ID: 7699446
    [Abstract] [Full Text] [Related]

  • 15. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
    Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD.
    Clin Cancer Res; 1998 Feb 01; 4(2):311-6. PubMed ID: 9516916
    [Abstract] [Full Text] [Related]

  • 16. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G, Patoia L, Giglietti A, Alessio M, Pelicci P, Grignani F.
    Bone Marrow Transplant; 1999 Nov 01; 24(9):971-9. PubMed ID: 10556956
    [Abstract] [Full Text] [Related]

  • 17. Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.
    Blumenthal RD, Alisauskas R, Lew W, Sharkey RM, Goldenberg DM.
    Exp Hematol; 1998 Aug 01; 26(9):859-68. PubMed ID: 9694507
    [Abstract] [Full Text] [Related]

  • 18. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
    Colnot DR, Quak JJ, Roos JC, van Lingen A, Wilhelm AJ, van Kamp GJ, Huijgens PC, Snow GB, van Dongen GA.
    J Nucl Med; 2000 Dec 01; 41(12):1999-2010. PubMed ID: 11138685
    [Abstract] [Full Text] [Related]

  • 19. The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer.
    Demetri GD.
    Pharmacotherapy; 1996 Dec 01; 16(3 Pt 2):94S-100S. PubMed ID: 8726588
    [Abstract] [Full Text] [Related]

  • 20. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L.
    Semin Oncol; 1995 Feb 01; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.